Cargando…
Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with glioma...
Autores principales: | Burger, Michael C., Mildenberger, Iris C., Wagner, Marlies, Mittelbronn, Michel, Steinbach, Joachim P., Bähr, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412312/ https://www.ncbi.nlm.nih.gov/pubmed/28353668 http://dx.doi.org/10.3390/ijms18040726 |
Ejemplares similares
-
A rare case of gliomatosis cerebri presenting as dementia
por: Gutch, Manish, et al.
Publicado: (2012) -
Impact of adjuvant chemotherapy for gliomatosis cerebri
por: Kong, Doo-Sik, et al.
Publicado: (2010) -
Gliomatosis Cerebri: Current Understanding and Controversies
por: Ranjan, Surabhi, et al.
Publicado: (2017) -
Gliomatosis Cerebri in the Brain of a Cat
por: Shrader, Stephanie, et al.
Publicado: (2016) -
Gliomatosis Cerebri: A Unique Presentation with Accompanying Clinical Nuance
por: Ordookhanian, Christ, et al.
Publicado: (2019)